Aniracetam

Toxicological Profile of a Chemical Derivative of 2-Pyrrolidinone

Summary

Complete toxicological screening with aniracetam, a nootropic agent, showed the drug to be very well tolerated by mice, rats, rabbits and dogs, after both single and repeated dose administration. No adverse effects on the reproductive system were seen and the compound was negative in a battery of mutagenicity tests. Lifelong treatment in mice and rats did not reveal any carcinogenic potential of the drug. The effects found in the various animal studies occurred only at extremely high doses and were in general of minor toxicological relevance. The therapeutic index of the compound is therefore considered to be very large.

This is a preview of subscription content, log in to check access.

References

  1. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research 31: 345–364, 1975

    Article  Google Scholar 

  2. Anonymous. Aniracetam. Drugs of the Future 6: 127–128, 1981

    Google Scholar 

  3. Anonymous. Aniracetam. Drugs of the Future 8: 251–252, 1983a

    Google Scholar 

  4. Anonymouse. Pramiracetam hydrochloride. Drugs of the Future 8: 795–796, 1983b

    Google Scholar 

  5. Anonymous. Aniracetam. Drugs of the Future 9: 211–212, 1984

    Google Scholar 

  6. Barrow WV, Taylor WJ. A rapid method for detecting malformations in rat fetuses. Journal of Morphology 127: 291–305, 1969

    PubMed  Article  CAS  Google Scholar 

  7. Cumin R, Bandle EF, Gamzu E, Haefely WE. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78: 104–111, 1982

    PubMed  Article  CAS  Google Scholar 

  8. Dawson AA. A note on the staining of the skeleton of cleared specimens with alizarin Red S. Stain Technology 1: 123–124, 1926

    Google Scholar 

  9. De Angelis L. Oxiracetam. Drugs of the Future 5: 405–407, 1980

    Google Scholar 

  10. De Angelis L. Etiracetam. Drugs of the Future 6: 552–553, 1981

    Google Scholar 

  11. Frantz CN, Mailing HV. The quantitative microsomal mutagenesis assay method. Mutation Research 31: 365–380, 1975

    PubMed  Article  CAS  Google Scholar 

  12. Green MHL, Bridges BA, Rogers AM, Horspool G, Muriel WJ, et al. Mutagen screening by a simplified bacterial fluctuation test: use of microsomal preparations and whole liver cells for metabolic activation. Mutation Research 48: 287–294, 1977

    PubMed  Article  CAS  Google Scholar 

  13. Ishidate M, Sofuni T, Yoshikawa K. Chromosomal aberration test in vitro as a primary screening test for environmental mutagens and/or carcinogens. GANN Monograph Cancer Research 27: 95–108, 1981

    CAS  Google Scholar 

  14. Moos WH, Davis RE, Schwarz RD, Gamzu ER. Cognition activators. Medical Research Reviews 8: 353–359, 1988

    Article  CAS  Google Scholar 

  15. Poschel BPH, Marriott JG, Gluckman MI. Pharmacology of the cognition activator pramiracetam (CI-879). Drugs Under Experimental and Clinical Research 9: 853–871, 1983

    CAS  Google Scholar 

  16. Salewski E. Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. Archiv für experimentelle Pathologie und Pharmakologie 247: 367, 1964

    Google Scholar 

  17. Schildler U, Rush DK, Fielding S. Nootropic drugs: animal models for studying effects on cognition. Drug Development Research 4: 567–576, 1984

    Article  Google Scholar 

  18. van Julsingha EB, Bennett CG. A dissecting procedure for the detection of anomalies in the rabbit foetal head. In Neubert D, et al. (Eds) Methods in prenatal toxicology, pp. 126–144, Thieme, Stuttgart, 1977

    Google Scholar 

  19. Zimmermann FK, Kern R, Rasenberger H. A yeast strain for simultaneous detection of induced mitotic crossing over, mitotic gene conversion and reverse mutation. Mutation Research 28: 381–388, 1975

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr Bernhard Schläppi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schläppi, B., Bürgin, H. & Gocke, E. Aniracetam. Drug Invest 5, 50–67 (1993). https://doi.org/10.1007/BF03258427

Download citation

Keywords

  • Drug Invest
  • High Dose Group
  • Bodyweight Gain
  • Aniracetam
  • Toxicological Profile